Teva and MAbxience Expand Strategic Partnership to Include an Additional Oncology Biosimilar Candidate
BofA Securities Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $22
Teva Pharmaceutical's US Affiliate Launches Octreotide Acetate for Injectable Suspension
Teva Announces Launch Of The First And Only Generic Version Of Sandostatin LAR Depot, In The U.S.
Why Are Analysts Bullish On Teva Pharmaceutical Industries Limited (TEVA) Right Now?
Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 A.m. ET on November 6, 2024
